Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Global Blood Therapeutics (GBT) Gains on Positive Results from Ongoing Sickle Cell Drug Trial
June 10, 2016 9:07 AM EDTGlobal Blood Therapeutics (NASDAQ: GBT) is gaining 21% pre-open trade after the company... More
Global Blood Therapeutics (GBT) Announces New Results from Ongoing Phase 1/2 GBT440-001 Study in Sickle Cell Disease
June 10, 2016 8:01 AM EDTGlobal Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced new results from its ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD) that further support the company's plans to develop GBT440 as a potential disease-modifying therapy for SCD. The data being presented today at the European Hematology Association's (EHA) 21st Congress in Copenhagen include a poster presentation of... More
